International journal of clinical oncology · 2026
Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suzuki Takanori, Matsuura Kentaro, Narahara Satoshi, Okayama Kohei, Okumura Fumihiro, Sobue Satoshi, Narita Kiyoto, Mizoshita Tsutomu, Kondo Hiromu, Kimura Yoshihide, Kato Daisuke, Hayashi Katsumi, Uojima Haruki, Hojo Mayumi, Murakami Shuko, Inoue Takako, Kawamura Hayato, Fujiwara Kei, Nojiri Shunsuke, Kataoka Hiromi, Tanaka Yasuhito
Аннотация
BACKGROUND: Increasing evidence indicates that vitamin D has anticancer effects. However, there are very limited data regarding the relationship between vitamin D levels and the efficacy or prognosis by atezolizumab plus bevacizumab (ATZ/BEV) for hepatocellular carcinoma (HCC). We sought to investigate this.
METHODS: This study included 142 HCC patients who were treated with ATZ/BEV as the first-line of systemic chemotherapy. Their initial treatment responses were evaluated using dynamic computed tomography or magnetic resonance imaging. Serum levels of 25-hydroxyvitamin D (vitamin D) were measured before treatment, and their associations with treatment efficacy and prognosis were analyzed.
RESULTS: Pretreatment vitamin D levels tended to be lower in patients who showed progressive disease (PD) at the initial response assessment than in those without PD (P = 0.098). Receiver operating curve analysis of pretreatment serum vitamin D levels for discriminating non-PD and PD at the initial therapeutic response yielded an area under the curve of 0.611, and the optimal cutoff value was determined to be 17.8 ng/mL. In addition, this cutoff value effectively stratified patients according to overall survival (OS) (high vs. low: not reached vs. 27.0 months, P = 0.022). Multivariate analysis showed that modified albumin-bilirubin grade (≥ 2a) (HR = 2.06; P = 0.018) and high serum vitamin D levels (≥ 17.8 ng/ml) (HR = 0.58; P = 0.046) were independently associated with OS.
CONCLUSIONS: Serum vitamin D levels before treatment may serve as a predictive biomarker for the prognosis in patients treated with ATZ/BEV for advanced HCC.
METHODS: This study included 142 HCC patients who were treated with ATZ/BEV as the first-line of systemic chemotherapy. Their initial treatment responses were evaluated using dynamic computed tomography or magnetic resonance imaging. Serum levels of 25-hydroxyvitamin D (vitamin D) were measured before treatment, and their associations with treatment efficacy and prognosis were analyzed.
RESULTS: Pretreatment vitamin D levels tended to be lower in patients who showed progressive disease (PD) at the initial response assessment than in those without PD (P = 0.098). Receiver operating curve analysis of pretreatment serum vitamin D levels for discriminating non-PD and PD at the initial therapeutic response yielded an area under the curve of 0.611, and the optimal cutoff value was determined to be 17.8 ng/mL. In addition, this cutoff value effectively stratified patients according to overall survival (OS) (high vs. low: not reached vs. 27.0 months, P = 0.022). Multivariate analysis showed that modified albumin-bilirubin grade (≥ 2a) (HR = 2.06; P = 0.018) and high serum vitamin D levels (≥ 17.8 ng/ml) (HR = 0.58; P = 0.046) were independently associated with OS.
CONCLUSIONS: Serum vitamin D levels before treatment may serve as a predictive biomarker for the prognosis in patients treated with ATZ/BEV for advanced HCC.